14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IBO vs IBG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Innovation Beverage Group Limited (IBG) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas IBG carries 45.2/100 (HOLD) at $0.71 (N/M Forward P/E, -187.6% operating margin).
Composite vs. Pillar Nuance: While IBG currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. -187.6% operating margin) and revenue trajectory (+16.7% vs. -38.6% YoY).
Technical & Structure Timing Caution: IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4); meanwhile IBG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBO vs IBG. Trailing 12-month operating profitability (IBO -12621.0% vs IBG -187.6%) and valuation multiples (IBO N/M vs IBG N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Beverages - Wineries & Distilleries value chain with $3.0M market capitalization and -187.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IBO vs IBG Key Questions & Quantitative Answers
As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Innovation Beverage Group Limited (IBG) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas IBG carries 45.2/100 (HOLD) at $0.71 (N/M Forward P/E, -187.6% operating margin). Composite vs. Pillar Nuance: While IBG currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. -187.6% operating margin) and revenue trajectory (+16.7% vs. -38.6% YoY). Technical & Structure Timing Caution: IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4); meanwhile IBG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IBO leads the Growth & Scale pillar: IBO posts +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (N/A gross margin, -12621.0% operating margin), compared with IBG at -38.6% YoY revenue growth and +0.0% YoY earnings growth on $2.8M TTM revenue (44.2% gross margin, -187.6% operating margin). On trailing 12-month operating scale, IBO generates $2.3M in USD-normalized revenue versus $2.8M for IBG. In operating R&D and SG&A reinvestment, IBO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBG.
IBO and IBG trade at balanced relative valuation multiples. IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 18.2x EV/Revenue (unreported FCF margin), whereas IBG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBO (71.2% ROE) versus IBG (-159.3% ROE) capital efficiency.
In options market volatility and institutional positioning, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.75β · 120% Vol realized risk). By comparison, IBG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.07β · 125% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.